Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Elacestrant Versus Standard Endocrine Therapy in Women and Men With Node-positive, Estrogen Receptor-positive, HER2-negative, Early Breast Cancer With High Risk of Recurrence-A Global, Multicenter, Randomized, Open-label Phase 3 Study

Next Previous
Trial Profile

Elacestrant Versus Standard Endocrine Therapy in Women and Men With Node-positive, Estrogen Receptor-positive, HER2-negative, Early Breast Cancer With High Risk of Recurrence-A Global, Multicenter, Randomized, Open-label Phase 3 Study

Status: Recruiting
Phase of Trial: Phase III

Latest Information Update: 13 Jun 2025

Price :
$35 *
Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Elacestrant (Primary) ; Anastrozole; Exemestane; Letrozole; Tamoxifen
  • Indications Early breast cancer; HER2 negative breast cancer
  • Focus Registrational; Therapeutic Use
  • Acronyms ELEGANT
  • Sponsors Stemline Therapeutics

Most Recent Events

  • 22 May 2025 According to a Menarini media release, data from this study will be presented at the 2025 American Society of Clinical Oncology (ASCO) Annual Meeting.
  • 30 Apr 2025 Trial design presented at the 116th Annual Meeting of the American Association for Cancer Research.
  • 13 Dec 2024 Trial design presented at the 47th Annual San Antonio Breast Cancer Symposium.

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top